ARCA biopharma and Oruka Therapeutics announce merger agreement

ARCA biopharma, Inc. (NASDAQ: ABIO) and Oruka Therapeutics have announced a definitive agreement to merge in an all-stock transaction, poised to reshape the chronic skin disease treatment landscape. The new entity, retaining the name Oruka Therapeutics, Inc., will focus on advancing a pipeline of potentially best-in-class biologics, including ORKA-001 and ORKA-002, targeting IL-23p19 and IL-17A/F…